JPMorgan Chase & Co. Acquires 23,934 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

JPMorgan Chase & Co. raised its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 18.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 151,835 shares of the company's stock after purchasing an additional 23,934 shares during the period. JPMorgan Chase & Co. owned approximately 0.53% of Krystal Biotech worth $23,786,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Wilmington Savings Fund Society FSB purchased a new stake in shares of Krystal Biotech during the third quarter valued at $40,000. Avanza Fonder AB purchased a new position in shares of Krystal Biotech in the fourth quarter worth approximately $119,000. KBC Group NV grew its position in Krystal Biotech by 46.3% during the fourth quarter. KBC Group NV now owns 939 shares of the company's stock valued at $147,000 after buying an additional 297 shares during the period. Blue Trust Inc. increased its holdings in Krystal Biotech by 74.4% during the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after buying an additional 433 shares during the last quarter. Finally, US Bancorp DE raised its position in Krystal Biotech by 8.7% in the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after acquiring an additional 82 shares during the period. Institutional investors own 86.29% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on KRYS. HC Wainwright restated a "buy" rating and issued a $221.00 price objective on shares of Krystal Biotech in a research note on Friday, February 28th. Chardan Capital upped their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Citigroup increased their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Finally, Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price target on the stock. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Krystal Biotech has an average rating of "Buy" and a consensus price target of $220.00.

Remove Ads

Krystal Biotech Stock Down 0.6 %

NASDAQ KRYS traded down $1.05 during trading hours on Tuesday, reaching $167.86. The company's stock had a trading volume of 29,344 shares, compared to its average volume of 294,476. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34. The company has a market capitalization of $4.85 billion, a price-to-earnings ratio of 56.14 and a beta of 0.75. The firm's 50-day moving average price is $174.09 and its 200-day moving average price is $172.15.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. Krystal Biotech's revenue for the quarter was up 116.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.30 earnings per share. Equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares of the company's stock, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Insiders own 14.10% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).